(-0.55%) 5 079.25 points
(-0.27%) 38 575 points
(-0.95%) 17 497 points
(0.19%) $82.97
(-0.67%) $1.642
(0.04%) $2 339.30
(0.33%) $27.44
(0.28%) $918.40
(-0.23%) $0.932
(-0.35%) $10.94
(-0.46%) $0.799
(-0.22%) $92.12
0.00% CHF 0.00440
Live Chart Being Loaded With Signals
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy...
Stats | |
---|---|
Today's Volume | 264 702 |
Average Volume | 527 088 |
Market Cap | 793 364 |
EPS | CHF0 ( 2024-03-30 ) |
Next earnings date | ( CHF0 ) 2024-05-13 |
Last Dividend | CHF0 ( N/A ) |
Next Dividend | CHF0 ( N/A ) |
P/E | -0.0200 |
ATR14 | CHF0 (0.00%) |
Obseva SA Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Obseva SA Financials
Annual | 2022 |
Revenue: | CHF19.64M |
Gross Profit: | CHF8.93M (45.46 %) |
EPS: | CHF-0.320 |
Q4 | 2022 |
Revenue: | CHF19.64M |
Gross Profit: | CHF8.93M (45.46 %) |
EPS: | CHF0.290 |
Q3 | 2022 |
Revenue: | CHF3.71M |
Gross Profit: | CHF3.71M (100.00 %) |
EPS: | CHF-0.130 |
Q2 | 2022 |
Revenue: | CHF0 |
Gross Profit: | CHF0 (0.00 %) |
EPS: | CHF-0.390 |
Financial Reports:
No articles found.
Obseva SA
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators